We provide the latest news
from the world of economics and finance
(RTTNews) - Alnylam Pharmaceuticals, Inc. (ALNY) Monday said its Phase 3 HELIOS-B study evaluating vutrisiran in Transthyretin amyloid cardiomyopathy (ATTR-CM) met primary goal.
In the study, patients with ATTR-CM were randomized to receive either vutrisiran or placebo for a period of up to 36 months. Results from the study showed statistically significant reduction in the composite of all-cause mortality and recurrent cardiovascular (CV) events in both the overall population and in the monotherapy population. Additionally, treatment with vutrisiran reduced all-cause mortality in the overall population and in the monotherapy population up to month 42.
Alnylam plans to file global regulatory submissions starting later this year including a supplmental New Drug Application to the FDA seeking priority review.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
© 2024 Lime Trading (CY) Ltd
Lime Trading (CY) Ltd is authorised and regulated by the Cyprus Securities and Exchange Commission in accordance with license No.281/15 issued on 25/09/2015. The "Just2Trade" trademark is owned by LimeTrading (CY) Ltd.
Registration Number: HE 341520
Address: Lime Trading (CY) Ltd
Magnum Business Center, Office 4B, Spyrou Kyprianou Avenue 78
Limassol 3076, Cyprus
Disclaimer:
All promotions, materials and information of this website may have applied conditions. Please contact the Company for further details
Trading on financial markets carries risks. The value of the investments can both increase and decrease and the investors may lose all their investment capital. In case of a leveraged product, the loss may be more than the initial capital invested. Detailed information on risks associated with trading on financial markets can be found in General Terms and Conditions for the Provision of Investment Services.